r Pre-ischaemic administration of aminooxiacetate (AOA), an inhibitor of the malate-aspartate shuttle (MAS), provides cardioprotection against ischaemia-reperfusion injury. The underlying mechanism remains unknown.
Introduction
The heart and other organs can be protected against lethal ischaemia-reperfusion (IR) injury by ischaemic preconditioning (IPC), by which brief non-lethal cycles of IR protect the myocardium against tissue damage by sustained ischaemia and subsequent reperfusion. The underlying mechanisms involve a reduction of mitochondrial reactive oxygen species (ROS) emission after reperfusion and an improvement of mitochondrial function (Halestrap et al. 2007) . To prevent IR injury in clinical settings and to further understand the specific role of cardioprotective pathways accessible for pharmacological intervention and modification by IPC, further investigation of the mitochondrial involvement in the mechanisms underlying the effect of IPC is necessary.
Mitochondria play a pivotal role in myocardial IR injury (Di Lisa & Bernardi, 2006) . During ischaemia, mitochondrial oxidative phosphorylation (OXPHOS) is largely suppressed as a result of hypoxia. However, reperfusion therapy induces an abrupt increase in the O 2 supply into the myocardium and a rapid re-establishment of mitochondrial OXPHOS with a resultant burst of ROS emission originating from highly active mitochondria ). By their proximity, mitochondria can be a primary target for their own ROS emission. The damaged mitochondria emit additional ROS and form a vicious cycle at later phase of reperfusion, which results in irreversible myocardial damage (Zweier & Talukder, 2006) .
The malate-aspartate shuttle (MAS) is the foremost biochemical pathway for transferring the reducing equivalent NADH from the cytosol to the mitochondrial matrix ( Fig. 1) . Although NADH is also synthesized in the mitochondrial matrix via the tricarboxylic acid (TCA) cycle, the MAS plays an important role in the achievement of maximal ATP production in the mitochondrial electron transport chain (ETC) because the mitochondrial inner membrane is impermeable to NADH (Purvis & Lowenstein, 1961) . Particularly in the heart, the MAS is a major shuttle for the transfer of cytosolic NADH (Safer, 1975) . We previously demonstrated that a transient inhibition of the MAS by a pre-ischaemic administration of aminooxyacetate (AOA), which is an inhibitor of amino acid transamination reactions, improved post-ischaemic haemodynamic recovery and reduced the final infarct size in isolated rat heart, and that similar effects were obtained with IPC (Stottrup et al. 2010) .
Both AOA administration and IPC reduce complex I (NADH)-linked mitochondrial OXPHOS in the normal heart (Stottrup et al. 2010) . This metabolic suppression of the mitochondria at the onset of reperfusion may be beneficial when mitochondrial OXPHOS is excessively activated. In addition, AOA washout is observed within a few minutes after reperfusion with an AOA-free perfusion buffer, indicating that the metabolic suppression by pre-ischaemic AOA administration is limited to ischaemia and early reperfusion (Lofgren et al. 2009 ). We therefore hypothesized that a transient inhibition of the MAS during ischaemia and at the onset of reperfusion may result in a reduction of mitochondrial oxidative stress and mitochondrial damage at later phase of reperfusion and that this mechanism may be an inherent component of the cardioprotection provided by IPC.
In the present study, we examined whether pre-and per-ischaemic administration of AOA reduces infarct size, preserves mitochondrial respiratory capacity and reduces mitochondrial ROS emission with attenuated oxidative damage during late reperfusion in ischaemic rat heart. We also compared the intermediary metabolic response of AOA with that of IPC in an IR-injury model of isolated rat heart to establish whether MAS inhibition with reduced transport of redox material to the mitochondrial oxidation is a central component of IPC.
Methods

Ethical approval
The present study was approved by the Danish Animal Experimental Inspectorate (Authorization No. 2008 / 561-1522 (NIH Publication No. 85-23, revised 1996) and also complied with the policy and regulations of The Journal of Physiology (Grundy, 2015) .
Animals
Male Wistar rats (280-320 g, M&B Taconic, Eiby, Denmark) were kept under a 12:12 h light/dark cycle at a constant temperature of 23°C and allowed unlimited access to food and water. Prior to the examination, all rats were fasted for 10-12 h.
Study design
Isolated perfused rat hearts were divided into seven groups (n = 7-8 in each group): (i) sham-operated hearts (Sham group); (ii) IR-injured hearts (IR group); (iii) IR-injured hearts with IPC by 2 × 5 min cycles of IR prior to sustained global no-flow ischaemia (IPC group); (iv) IR-injured hearts co-perfused with 0.2 mmol L −1 AOA for 5 min prior to global no-flow ischaemia (pre-AOA group); (v) IR-injured hearts co-perfused with 0.2 mmol L −1 AOA and 5 mmol L −1 dimethyl succinate (DiSuc), cell permeable succinate precursors, for 5 min prior to global no-flow ischaemia (AOA + DiSuc group); (vi) IR-injured hearts co-perfused with 0.2 mmol L −1 AOA for 5 min at the end of global no-flow ischaemia (per-AOA group); and (vii) IR-injured hearts treated with pre-ischaemic AOA and IPC (AOA + IPC group) (Fig. 2) .
In the present study, we conducted three experimental series: a mitochondrial respiratory study (Series I), a microdialysis study (series II) and an infarct size study (series III). In experimental series I, hearts were perfused with a modified Krebs-Henseleit buffer (KHB) containing 3% BSA with either glucose (11 mmol L −1 ) or glucose (11 mmol L −1 ) + free fatty acids (FFA) (0.4 mmol L −1 palmitate). Experimental series II and III were performed with glucose (11 mmol L −1 ) as the only substrate.
After isolation, the rat hearts were stabilized for 40 min, followed by 30 min of global no-flow ischaemia and 30 min of reperfusion (Fig. 2) . A total of 120 min of reperfusion was only given in experimental series III to ensure washout of lactate dehydrogenase before infarct staining. After 30 min of reperfusion, the left ventricular cardiac muscle was quickly removed and divided into two parts. One part was stored in an ice-cold relaxing solution (BIOPS; in mmol L −1 : 2.77 CaK 2 EGTA, 7.23 EGTA, 20 taurine, 6.56 MgCl 2 , 5.77 ATP, 15 phosphocreatine, 0.5 dithiothreitol and 50 4-morpholineethanesulphonic acid; pH 7.1) and transferred the same day from the facility in the city of Aarhus, Denmark to Copenhagen immediately after the removal of cardiac muscle for the measurements of mitochondrial respiratory capacity, mitochondrial fatty acid oxidation and mitochondrial ROS emission. The second part was quickly frozen in liquid nitrogen and stored at −80°C for later analyses, including those of the mitochondrial enzymatic activities, oxidative damage and protein contents.
Preparation of isolated perfused heart
Isolated perfused rat hearts (Langendorff-perfusion) were prepared as described previously (Stottrup et al. 2010 Figure 2 . Study design Two different perfusion solutions containing glucose or glucose + FFA as substrates for metabolism during the isolation procedures of rat hearts were used. Isolated perfused rat hearts were divided into seven groups (n = 7-8 in each group): Sham-operated hearts (Sham group), IR-injured hearts by 30 min of global no-flow ischaemia and reperfusion (IR group), IR-injured hearts with IPC induced by 2 × 5min cycles of IR prior to global no-flow ischaemia (IPC group), IR-injured hearts with a pre-ischaemic administration of AOA to inhibit the MAS during ischaemia and early reperfusion (Pre-AOA group), IR-injured hearts co-perfused with 0.2 mmol L −1 AOA and 5 mmol L −1 dimethyl succinate for 5 min prior to global no-flow ischaemia (AOA + DiSuc group), IR-injured hearts co-perfused with 0.2 mmol L −1 AOA for 5 min during global no-flow ischaemia (per-AOA group) and IR-injured hearts treated with pre-ischaemic AOA and IPC (AOA + IPC group). Three experimental series were conducted: Experimental series I was conducted using both glucose and glucose + FFA, and experimental series II and III were conducted using only glucose as the substrate for perfusion solutions.
conditions of stunning during cannulation into the aorta with the anaesthesia, the heart was quickly excised and mounted in an isolated perfused heart apparatus (IH-SR type 844/1; HSE, March-Hugstetten, Germany) and perfused at a constant pressure of 80 mmHg at 37°C. An intraventricular balloon (Size 7; HSE) was inserted into the heart to simulate preload. After 10 min of non-recirculating perfusion to clear the heart from blood, the perfusate was switched to KH buffer supplemented with 3% acid-free BSA and either 0 or 0.4 mmol L −1 palmitate, and recirculation was commenced according to the protocol. The perfusion solution was oxygenated with 95% O 2 and 5% CO 2 by use of a membrane oxygenator (Radnoti, Monrovia, CA, USA) containing O 2 permeable tubing (Helix, Kaiserslautern, Germany).
Mitochondrial enzymatic activity
We measured citrate synthase (CS) and β-hydroxyacylCoA dehydrogenase (HAD) activities in the cardiac tissue homogenates by spectrophotometry as described previously (Christiansen et al. 2015) and the results are expressed as μmol min −1 mg −1 tissue.
Protein content of mitochondrial ETC complexes
Myocardial cell lysates were isolated in lysis buffer (in mmol L −1 : 250 NaCl, 50 Hepes, 10% glycerol, 1% Triton X-100, 1.5 MgCl 2 , 1 EGTA, 10 Na 4 P 2 O 7 , 1 NaF and 800 μmol L −1 Na 3 VO 4 ; pH 7.5) and centrifuged at 12 000 g for 10 min. The supernatant was collected and separated by 12.5% SDS-PAGE and transferred to a nitrocellulose membrane (0.45 μm, 162-0115; Bio-Rad, Hercules, CA, USA) using 10 mmol L −1 sodium tetraborate buffer. The membranes were blocked in 5% BSA in TBS-T buffer (in mmol L −1 : 10 Tris-HCl, 150 NaCl and 0.05% Tween 20; pH 7.5) for 1 h at room temperature. The membranes were then left to incubate overnight at 4°C with primary antibody (total OXPHOS rodent antibody cocktail, dilution 1:4000, MS604; MitoSciences, Eugene, OR, USA). The blots were washed, incubated with horseradish peroxidase-conjugated secondary antibodies and visualized with a chemiluminescence system (Immun-Star Chemiluminescent; Bio-Rad). The bands were analysed using ImageJ (NIH, Bethesda, MD, USA) to determine protein expression.
Preparation of permeabilized fibres
After careful manual dissection of the myocardial tissue, fibre bundles were permeabilized by gentle agitation for 30 min in an ice-cold BIOPS solution with saponin (50 μg mL −1 ) (Christiansen et al. 2015) . After permeabilization, the fibres were rinsed twice by agitation for 10 min in an ice-cold respiration medium, MiR05 (in mmol L −1 : 110 sucrose, 60 K-lactobionate, 0.5 EGTA, 0.1% BSA, 3 MgCl 2 , 20 taurine, 10 KH 2 PO 4 and 20 Hepes; pH 7.1).
Mitochondrial respiratory capacity
We measured the mitochondrial respiratory capacity with non-fatty acid substrates in the permeabilized cardiac muscle fibre at 37°C using a high-resolution respirometer (Oxygraph-2k; Oroboros Instruments, Innsbruck, Austria) as described previously (Christiansen et al. 2015) . All respiratory measurements were carried out in duplicate after hyperoxygenation to avoid any potential O 2 limitation to respiration.
After the addition of the permeabilized cardiac muscle fibre (ß1.5 mg) to the chamber filled with 2 mL of MiR05 in the Oxygraph-2k respirometer, the respiratory substrates and inhibitors were added in the order:
). The integrity of the mitochondrial outer membrane was tested by the addition of cytochrome c, and the data were eliminated when the increase in the oxygen consumption rate was >10% as a sign of a damaged mitochondrial outer membrane. The respiratory rates (i.e. the O 2 consumption rates) are expressed as the O 2 flux normalized to the cardiac muscle mass (pmol s
wet weight of cardiac muscle). The respiratory control ratio (RCR) was calculated as state 3 respiration/state 2 respiration.
Mitochondrial fatty acid oxidation
We also used the Oxygraph-2k respirometer to measure the capacity of mitochondrial fatty acid oxidation in the permeabilized cardiac muscle fibre, as described previously (Christiansen et al. 2015) . Respiratory substrates including a fatty acid were added in the order:
Mitochondrial ROS emission
Because superoxide (O 2 − ) is a short-lived ROS that is unsuitable for the continuous measurement of ROS, we measured hydrogen peroxide (H 2 O 2 ) emission from the permeabilized cardiac muscle fibre in each respiratory state at 37°C using a spectrofluorometer (SAFAS Xenius; SAFAS Monaco, Monaco) to assess the potential capacity of mitochondrial ROS emission, after converting mitochondrial O 2 − into H 2 O 2 by the addition of J Physiol 595.12 superoxide dismutase (SOD) as described previously (Stride et al. 2013; Christiansen et al. 2015) . H 2 O 2 reacts with Amplex Red (Molecular Probes, Carlsbad, CA, USA) in a 1:1 stoichiometry catalysed by horseradish peroxidase, which yields the fluorescent compound resorufin (excitation 560 nm, emission 590 nm). The fluorescence of resorufin was monitored continuously throughout the measurement. The permeabilized cardiac muscle fibre was added to 500 μL of MiR05 with SOD (90 U mL −1 ), Amplex Red (0.05 mmol L −1 ) and horseradish peroxidase (12 U mL −1 ) in the cuvette in the SAFAS Xenius spectrofluorometer. The substrates, ADP and inhibitors were then added in the order: (i) glutamate (10 mmol L −1 ) and malate (2 mmol L −1 ); (ii) ADP (5 mmol L −1 ); (iii) succinate (10 mmol L −1 ); (iv) oligomycin (2 μg mL −1 ); and (v) rotenone (0.5 μmol L −1 ) and antimycin A (2.5 mmol L −1 ) (i.e. the same as that used for the measurements of mitochondrial respiratory capacity with non-fatty-acid substrates). Before the study, five different concentrations of H 2 O 2 were added to establish a standard curve in advance. The H 2 O 2 emission rate in each respiration is expressed as pmol min −1 mg −1 wet weight of cardiac muscle.
Oxidative damage
Oxidative damage was assessed by the measurement of thiobarbituric acid reactive substances (TBARS) in myocardial tissue homogenates, as described previously (Christiansen et al. 2015) . TBARS were spectrophotometrically measured after the reaction of malondialdehyde and thiobarbituric acid under high temperatures, and the results are expressed as nmol g −1 tissue.
Myocardial interstitial concentrations of metabolites assessed by microdialysis
Myocardial interstitial concentrations of metabolites were assessed by microdialysis, which is a validated technique for measurements of the myocardial metabolite concentration (Kavianipour et al. 2003) . After the hearts were mounted in the Langendorff model in experimental series II, a microdialysis probe (membrane length 4 mm, cut-off 6 Da; AgnTho's, Lidingoe, Sweden) was inserted into the free wall of the left ventricle. The microdialysis probe was connected to a microdialysis pump (Univentor Limited, Zejtun, Malta) and perfused at a flow speed of 1 μL min −1 with KHB solution deoxygenated with 95% N 2 and 5% CO 2 . Following the implantation, a 20 min stabilization period was allowed for the metabolites to reach equilibrium in the perturbed tissue. We collected samples at 10 min intervals using a microdialysis vial sampler (Univentor Limited) with immediate cooling at 4°C and later at −80°C. Samples were analysed by liquid chromatography and mass spectrometry as described previously (Stottrup et al. 2010) .
Infarct size
Rat hearts from experimental series III were frozen at −80°C, sliced (1.5 mm thick) and vital stained with 1% 2,3,5-triphhenyltetrazoliumchloride to delineate areas of infarction. Area-at-risk and infarct size were assessed using Image J software and weighted with the wet weight of the individual slices. Finally, the infarct size/area-at-risk ratio was calculated for each heart.
Statistical analysis
The results are expressed as the mean ± SEM and a between-group comparison of means was performed by one-way ANOVA. Microdialysis measurements were analysed as the area under the curve during stabilization, ischaemia and reperfusion, respectively, and compared using one-way ANOVA. To protect against increased risk of type I error arising from the use of multiple comparisons, a Bonferroni test was applied for all comparisons. All statistical analyses were performed using Prism, version 5.0 (GraphPad Software, La Jolla, CA, USA). P < 0.05 was considered statistically significant.
Results
Mitochondrial enzymatic activities
The enzymatic activities of CS, an enzyme of the TCA cycle, and HAD, an enzyme of fatty acid β-oxidation, in the cardiac muscle were not different between the groups in either type of perfusion buffer during late reperfusion (Fig. 3A) .
Protein content of mitochondrial ETC complexes
Representative blots of mitochondrial ETC complexes I-V are shown in Fig. 3B . We found no significant difference in the protein content of the mitochondrial ETC complexes I-V in the cardiac muscle between groups, regardless of the perfusion buffer during late reperfusion (Fig. 3C) .
Mitochondrial respiratory capacity
The mitochondrial respiratory capacity in the permeabilized cardiac muscle fibre was evaluated with non-fatty acid substrates during late reperfusion as shown in Figs 4A-D. A representative graph shows mitochondrial respiratory capacity from sham-operated rat heart (Fig. 4A) . State 2 (non-ADP-stimulated) respiration with glutamate and malate (which are both complex I-linked substrates) did not differ between the groups in either type of perfusion buffer (Fig. 4B) . State 3 (ADP-stimulated) respiration with glutamate and malate was significantly reduced in the IR compared to the sham group. IPC and the pre-ischaemic administration of AOA increased the state 3 respiration with glutamate and malate in both types of perfusion buffer compared to the IR group (Fig. 4B) , which is consistent with the increase in the RCR, an index of coupled mitochondrial respiratory capacity independent of mitochondrial density, in both the IPC and AOA groups (Fig. 4C) . By contrast, we found no differences in state 3 respiration with glutamate, malate and succinate, a complex I+II-linked respiratory capacity, or the RCR between the groups in either type of perfusion buffer (Fig. 4B and D) . State 4o respiration (i.e. state 4 respiration with oligomycin; non-ADP-stimulated respiration) and residual oxygen consumption (ROX; the oxygen consumption unrelated to respiration) were also comparable between the groups in either type of perfusion buffer (Fig. 4B) . 
Mitochondrial fatty acid oxidation
We observed no difference in state 2 respiration with malate and octanoyl-L-carnitine in the permeabilized cardiac muscle fibre between the groups in either type of perfusion buffer during late reperfusion (Fig. 5A) . The state 3 respiration with malate and octanoyl-L-carnitine was significantly lower in the IR group compared to the sham group irrespective of the perfusion buffer (Fig. 5A) . By contrast, compared to the IR group, the IPC significantly increased the state 3 respiration with malate and octanoyl-l-carnitine with the perfusion buffer of glucose + FFA and AOA treatment significantly increased the state 3 respiration with malate and octanoyl-L-carnitine with both types of perfusion buffer (Fig. 5A ). These respiratory findings were reflected in the RCR, which decreased in the IR group and was improved by both IPC and AOA treatment (Fig. 5B ).
Mitochondrial ROS emission and oxidative damage
The mitochondrial H 2 O 2 emission during state 3 with glutamate and malate in the permeabilized cardiac muscle fibre during late reperfusion was significantly higher in the IR groups compared to the sham group with either type of perfusion buffer (Fig. 6A) . IPC and AOA treatment attenuated the excess emission of H 2 O 2 originating from the IR-injured cardiac mitochondria with both perfusion buffers, except for the IPC with the glucose + FFA perfusion buffer (Fig. 6A) . H 2 O 2 emission per O 2 consumption in state 3 with glutamate and malate was significantly elevated in the IR group compared to the sham group and was diminished by IPC and the pre-ischaemic administration of AOA (Fig. 6B) . We observed no significant differences in mitochondrial H 2 O 2 emission in other respiratory states or substrates between groups with either perfusion buffer (data not shown). Consistent with the changes in mitochondrial ROS emission during state 3 with glutamate and malate, the levels of TBARS (i.e. lipid peroxides) in the cardiac muscle during late reperfusion were significantly higher in the IR group compared to the sham group (Fig. 6C ). IPC and AOA treatment attenuated the myocardial TBARS level to the same as that of the sham group (Fig. 6C) . Figure 7 shows myocardial interstitial concentrations of metabolites. Before the index ischaemia, the myocardial interstitial concentrations of the TCA intermediates, citrate, succinate and fumarate were similar in all groups and IPC increased the myocardial lactate and malate concentration before the induction of ischaemia. 
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Figure 7. Myocardial interstitial concentrations of metabolites
The myocardial interstitial concentrations of lactate, TCA intermediates (citrate, glutamate, succinate, fumarate and malate) and purine metabolites (adenosine, hypoxanthine, inosine and xanthine) during stabilization, global no-flow ischaemia and reperfusion. Data are the mean ± SEM. The area under the curve has been calculated for each period and compared using one-way ANOVA. † P < 0.05 IPC or AOA vs. IR. ‡ P < 0.05 IPC vs. AOA.
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During ischaemia, the interstitial lactate concentration was significantly higher in all groups exposed to IR compared to the sham group, as expected, and the increase was partly attenuated in the IPC group compared to the IR group. The interstitial concentration of glutamate was significantly increased in the IR, IPC and AOA groups during ischaemia and the early phase of reperfusion compared to the sham group. The increase was higher in the IPC group compared to the IR and AOA groups during ischaemia but, after reperfusion, the increase became similar between groups. At the end of ischaemia and during reperfusion, the interstitial concentrations of succinate and malate were significantly lower in the AOA group compared to the IR and IPC groups, although these differences disappeared at the later phase of reperfusion. At the end of stabilization, IPC increased the concentration of purine metabolites. During ischaemia, the interstitial concentrations of adenosine, inosine, xanthine and hypoxanthine were increased in all of the study groups except the sham group. AOA administration did not change the purine concentrations during early reperfusion compared to the IR group, whereas IPC was associated with a decrease in the adenosine and inosine concentrations. IPC but not AOA administration changed the xanthine concentrations in the reperfusion. Hypoxanthine concentrations did not differ between the interventions. Figure 8 show that IPC significantly reduced infarct size compared to the IR group. Pre-ischaemic administration of AOA reduced infarct size to the same extent as IPC. However, when pre-ischaemic AOA administration was combined with dimethyl succinate, the protection was abrogated and the infarct size was comparable to the IR group. We found no significant difference in the effect of infarct size reduction between pre-and per-ischaemic administration of AOA, indicating that the difference in timing with respect to adding AOA before and during ischaemia does not influence the effect of AOA treatment on infarct size. Although a combination of pre-ischaemic AOA treatment and IPC reduced infarct size compared to the IR group, we found no additional effect compared to each IPC or AOA group.
Infarct size
Discussion
The main finding of the present study was that the transient inhibition of the MAS during ischaemia and the initial few minutes of reperfusion provided by a pre-ischaemic administration of AOA preserved the mitochondrial respiratory capacity at a later phase of reperfusion in isolated rat hearts. Moreover, AOA treatment abolished the excess emission of mitochondrial ROS during late reperfusion, which is consistent with the lowered myocardial oxidative damage. The reduced infarct size by AOA treatment after reperfusion may be attributable to the mitochondrial protection. The protective effects of the transient inhibition of the MAS on the mitochondrial respiratory capacity and mitochondrial oxidative stress were similar to those of IPC. However, AOA treatment, but not IPC, decreased the myocardial interstitial respiratory substrates at the onset of reperfusion, indicating that different mechanisms related to metabolic regulation may underlie the mitochondrial protection afforded by the inhibition of the MAS from IPC in the IR-injured heart. IPC activates a variety of signal transduction pathways that ultimately converge at the mitochondrial respiratory chain level (Liem et al. 2008) . The improvement of mitochondrial function and the attenuation of oxidative stress during ischaemia and subsequent reperfusion are important for the mediation of cardioprotection (Vanden Hoek et al. 2000; Kevin et al. 2003) . Among the mitochondrial ETC complexes, complex I is a major site of electron entry into the ETC, as well as ROS emission (Liem et al. 2008) . Indeed, it has been shown that excess ROS originating from mitochondrial ETC complex I contributes to the progression of various diseases, such as congestive heart failure and neurodegenerative disorders (Ide et al. 1999; Tretter et al. 2004) . Previous studies have shown that IPC may preserve mitochondrial function after IR via transient inhibition of mitochondrial ETC complexes, such as complexes I and II (Pasdois et al. 2006; Hill & Darley-Usmar, 2008; Wojtovich & Brookes, 2008; Chouchani et al. 2013) .
In the present study, the mitochondrial complex I-linked OXPHOS capacity was clearly impaired with increased ROS emission originating from complex I during late reperfusion in IR-injured rat heart. Notably, the transient inhibition of the MAS by AOA treatment improved the mitochondrial complex I-linked OXPHOS capacity and diminished the mitochondrial complex I-linked ROS emission during late reperfusion in the IR-injured hearts. A sustained emission of higher ROS after a myocardial infarction (MI) contributes to left ventricular remodelling via the stimulation of inflammatory cytokines, causing left ventricular systolic and diastolic dysfunction (Hori & Nishida, 2009 ). Therefore, the preserved mitochondrial respiratory capacity with reduced mitochondrial oxidative stress observed in the present study appears to be beneficial for preventing left ventricular remodelling in the chronic stage of MI after reperfusion therapy.
We observed that, in the IR injury, the myocardial fatty acid oxidation assessed by mitochondrial state 3 respiration with fatty acids was impaired. Because the main electron entry sites of fatty acids in the mitochondrial ETC after β-oxidation are complexes I and III via NADH and electron transfer flavoprotein (ETF) via FADH 2 (Eaton, 2002) , the decreased mitochondrial state 3 respiration with fatty acids may reflect an impaired mitochondrial complex I and/or ETF-linked OXPHOS capacity in IR injury. As far as HAD activity may represent β-oxidation, this did not change with either intervention, and thus the reducing equivalents from fatty acids were not a limiting factor. We then observed that the transient inhibition of the MAS by AOA treatment improved the state 3 respiration with fatty acids during late reperfusion in the IR-injured hearts. A reduced capacity of fatty acid oxidation after reperfusion has been shown to play a crucial role in the progression of left ventricular remodelling in the chronic phase of IR injury (Lou et al. 2013) . Taken together, our findings demonstrate that it is possible to preserve mitochondrial fatty acid oxidation after reperfusion by AOA treatment, and these results also provide proof-of-concept evidence that limiting the transportation of respiratory substrates into the mitochondria may prevent myocardial IR injury.
We also investigated whether a restricted transportation of substrates into the mitochondria during early reperfusion could prevent further mitochondrial damage during late reperfusion, on the basis of the concept that inhibition of the MAS works like a graded reperfusion regime via the limited entry of NADH into the mitochondria at the onset of reperfusion when damaged mitochondria are suddenly activated with a burst of mitochondrial ROS (Fig. 9) . A burst of ROS originating from the mitochondria in combination with the Ca 2+ overload after reperfusion may extend mitochondrial dysfunction beyond that caused by ischaemia alone and lead to additional cell death during reperfusion (Di Lisa & Bernardi, 2006; Zweier & Talukder, 2006; Hausenloy & Yellon, 2008) . Our findings indicate that preserved mitochondrial respiratory capacity with lowered mitochondrial ROS emission during late reperfusion may be the central mechanism of the cardioprotection by AOA treatment against IR injury observed in our previous study (Stottrup et al. 2010) .
Another possible mechanism of cardioprotection by transient inhibition of the MAS may be an attenuated accumulation of succinate, an intermediate of the TCA cycle, in the myocardium during ischaemia. A recent study showed that an accumulation of succinate in the myocardium during ischaemia can be a driving force of ROS emission originating from mitochondrial complex I via reverse electron transport from complex II (succinate dehydrogenase) to complex I at the onset of reperfusion, which may contribute to myocardial IR injury (Chouchani et al. 2014 ). Our present microdialysis measurements of intermediary metabolites revealed decreased concentrations of succinate in the AOA-treated hearts during ischaemia and early reperfusion, recapitulating the importance of the MAS as the main carbon source for succinate during ischaemia (Chouchani et al. 2014 Figure 9 . A possible mechanism of preservation of the mitochondria during late reperfusion in the IR-injured heart by inhibition of the MAS Transient inhibition of the MAS aiming at ischaemia and early reperfusion works like a break against the acceleration of mitochondrial activity at the onset of reperfusion via a limited entry of NADH and respiratory substrates into the mitochondria. The gradual wake-up of the mitochondria induced by the inhibition of the MAS during early reperfusion may reduce the excess emission of mitochondrial ROS, which results in the preservation of the mitochondria during late reperfusion.
J Physiol 595.12 of succinate in the cardiac muscle during ischaemia by AOA treatment may therefore reduce mitochondrial damage after reperfusion in the IR-injured heart. The TCA cycle operates in two regulatory spans: acetylCoA to α-ketoglutarate and α-ketoglutarate to oxaloacetate (Randle et al. 1970) . We found that a pre-ischaemic administration of AOA affected the myocardial interstitial concentration of second-span metabolites in the TCA cycle with a decrease in succinate and malate during ischaemia. AOA completely inhibited the aspartate aminotransferase of the MAS and resulted in a discontinuation of the conversion of fumarate to malate. During early reperfusion, the second-span metabolites continued to be down-regulated but were increased at the end of the protocol, indicating the contribution of a gradual 'wake-up' in cardiac intermediary metabolism after AOA washout from the myocardium.
However, IPC did not influence the second-span metabolite concentrations. The mitochondrial preserving effect of IPC therefore appears to be downstream of succinate oxidation, including an inhibition of complex II (Pasdois et al. 2006; Wojtovich & Brookes, 2008) and an inhibition of the transition of complex I to its active state during early reperfusion (Chen et al. 2006; Nadtochiy et al. 2009; Chouchani et al. 2013) , which may also prevent ROS emission and has been shown to protect against IR injury. In the present study, we observed no additional effect of reducing infarct size when AOA treatment and IPC were combined, indicating that IPC may act on the same pathway in the prevention of ROS emission. The ATP degradation end products (i.e. adenosine, inosine, hypoxanthine and xanthine) increased during ischaemia as expected and this was observed in cardiac tissue by Kakhniashvili et al. (1997) . We detected an amplified reduction in the interstitial concentrations after reperfusion in the IPC-treated hearts, indicating an energy-conserving effect possibly by a favorable attenuation of the AMP-dependent activation of the purine nucleotide cycle. The mechanisms behind this conservational effect are not yet clear, although activation of the purine nucleotide cycle has been shown as a parallel mechanism behind succinate accumulation during ischaemia and early reperfusion driving ROS release and IR injury (Chouchani et al. 2014) . Our data suggest that the cardioprotective properties of IPC are not by a reduced succinate accumulation during ischaemia, although purine metabolites are attenuated. This again indicates that the underlying mechanism is downstream of succinate oxidation.
In the present study, we found no significant difference in the effects of mitochondrial respiratory capacity and mitochondrial oxidative stress between AOA treatment and IPC in myocardial IR injury, which raises the possibility that a pre-ischaemic administration of AOA offers preconditioning-like mitochondrial protection. However, the concentrations of myocardial interstitial TCA intermediates during ischaemia and early reperfusion in the AOA group differed from those of the IPC group, supporting the existence of different mechanisms for the preservation of mitochondria by AOA and IPC in IR-injured hearts. In addition, our findings that a per-ischaemic AOA administration unrelated to IPC reduced infarct size after reperfusion to the same extent as that of a pre-ischaemic AOA administration eliminate the possibility of preconditioning-like effect of AOA treatment.
Other studies have demonstrated cardioprotection by a transient mitochondrial metabolic shutdown after reperfusion in animal models of IR injury by using mitochondrial inhibitors, such as rotenone (a complex I inhibitor) and hydrogen sulphide (a complex IV inhibitor) (Lesnefsky et al. 2004; Elrod et al. 2007 ). However, the majority of mitochondrial inhibitors have direct and strong effects on the mitochondrial ETC and are toxic for humans. In this regard, a MAS inhibitor indirectly affects the mitochondrial ETC by a mild suppression of mitochondrial OXPHOS via the alteration of NADH/NAD + in the mitochondria (Barron et al. 1998) . Moreover, a reversible inhibition of mitochondrial respiratory activity during ischaemia and early reperfusion may be important to preserve mitochondrial function during the later phase of IR injury. Therefore, a short-lived and reversible inhibitor of the MAS may be a potential therapeutic option to prevent myocardial IR injury in humans (e.g. an intracoronary administration of a MAS inhibitor immediately before percutaneous coronary intervention). AOA, a non-specific inhibitor of amino acid transamination reactions, is not clinically applicable (Gonzalez-Mateos et al. 1993) . Further studies are needed to explore the role of the MAS in myocardial IR-injury using more specific inhibitors of the MAS.
Some study limitations should be acknowledged. First, we used an ex vivo, non-working isolated animal heart model without neurohormonal influences to study IR injury, which limits the transferability of our findings to in vivo physiology. Second, our buffer did not contain insulin and does not reflect completely normal physiological conditions. All perfusions had added 3% BSA, and we used palmitate because it is the predominant circulating FFA in vivo. Other FFAs may be metabolized differently. The concentration of the FFAs (0.4 mM) reflected the physiological concentration used in other studies (Folmes et al. 2009 ). Third, we used only glucose as a perfusion buffer in the experimental series II and III because we confirmed that types of perfusion buffer did not influence the effect of AOA and IPC on mitochondrial function in IR injury in the experimental series I. Fourth, we used permeabilized myocardial fibres for high-resolution respirometry. This is a validated method to investigate the mitochondria in situ, at the same time offering the advantages of a smaller sample size, a reduced preparation time and the examination of all mitochondria in the cells (Pesta & Gnaiger, 2012) . Before examination, the samples were kept in ice-cold preservation-buffer for an average of 7.62 ± 0.09 h as a result of transportation. This timeframe is without damage to mitochondrial integrity and performance (Kuznetsov et al. 2000) . Fifth, the microdialysis samples were collected in 10 min spans to ensure sufficient material for analysis. This may limit the interpretation as a result of the low temporal resolution compared to the rapid changes that occur during early reperfusion. Finally, we used AOA for inhibition of the MAS. AOA is often used but is a non-specific inhibitor of the MAS. We could not completely eliminate the possibility of other mechanisms beyond MAS inhibition by AOA treatment, although AOA is the only short-lived and reversible inhibitor of the MAS.
In conclusion, transient inhibition of the MAS during ischaemia and early reperfusion induced by a pre-ischaemic administration of AOA preserved mitochondrial respiratory capacity and prevented excessive ROS emission from the mitochondria during late reperfusion in IR-injured rat heart, which results in reduced infarct size. Even though the effects of MAS inhibition and IPC on the mitochondrial level are similar, downregulated myocardial TCA-cycle intermediates at the onset of reperfusion by AOA treatment, but not IPC, suggest that the mechanisms underlying the protection differ.
